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Alzheimer’s disease (AD) is known for its debilitating symptoms and poor prognosis.  
Current treatments for AD focus on managing symptoms.  However, despite intense research 
into neurodegenerative diseases, there is still a dearth of therapies targeted at the underlying 
mechanisms of the disease.  Oxidative stress (OS) and inflammation are cellular phenomena 
thought to be key to the progression of the disease. Critically, peroxiredoxin 6 (Prx6), an 
antioxidant protein with multiple functions, has been identified from mammalian studies as a 
potential regulator of both OS and inflammation that may have a specific effect on AD.  This 
project seeks to elucidate the role of Prx6 in AD as well as the underlying mechanisms.  
Drosophila provide a convenient model for this investigation because they express two highly 
conserved homologs of mammalian Prx6: dPrx6005, with only peroxidase activity, and 
v 
 
dPrx2540, with both peroxidase activity and phospholipase-A2 activity which may influence 
inflammation. If this phospholipase-A2 activity promotes inflammation, dPrx2540 (and Prx6 in 
humans) could be exacerbating AD progression.  Lifespan experiments show that flies under-
expressing dPrx2540 in an AD background have significantly improved lifespan, suggesting that 
dPrx2540 may indeed exacerbate AD.   Surprisingly, however, flies over-expressing dPrx2540 
also had a small increase in lifespan, suggesting the role of dPrx2540 may be more complex.  
Further lifespan experiments, with greater expression levels of dPrx2540, are planned to tease 
apart the conundrum of beneficial results in both over- and under-expression experiments.  
Experiments measuring the expression of antimicrobial peptides as markers of inflammation 
suggest that neuronal expression of dPrx2540 alone or of Aβ42 alone do not cause inflammation 
in fly heads.  CRISPR methodology was used to generate flies with all endogenous copies of 
dPrx2540 removed (2540null) in order to more rigorously investigate the mechanisms of how 
dPrx2540 may influence AD.  These 2540null flies exhibit reduced lifespan and fertility.  Mutant 
dPrx2540 constructs with either peroxidase or phospholipase-A2 activities ablated will be 
crossed into the dPrx2540null background and further into the AD background.  
vi 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES ..................................................................................................................... viii 
LIST OF TABLES .......................................................................................................................... x 
ACKNOWLEDGEMENTS .......................................................................................................... xi 
CHAPTERS 
1.  INTRODUCTION ......................................................................................................... 1 
1.1  Background ...................................................................................................... 1 
1.2  Hypothesis ........................................................................................................ 3 
1.3  Objectives ........................................................................................................ 4  
2.  METHODS .................................................................................................................... 6 
2.1  The Gal4-UAS System and Experimental Crosses .......................................... 6 
2.2  Transgenic Drosophila Lines ........................................................................... 7 
2.3  Protein Isolation and Western Blots ................................................................ 9 
2.4  RNA Isolation and qPCR ............................................................................... 10 
2.5  DNA Isolation, PCR, and Electrophoresis ..................................................... 11 
2.6  Lifespan Experiments .................................................................................... 12
vii 
 
2.7  Fertility Assay ................................................................................................ 13 
2.8  CRISPR .......................................................................................................... 13 
2.9  Molecular Cloning ......................................................................................... 16 
3. RESULTS ..................................................................................................................... 18 
3.1  CRISPR Deletion of Endogenous dPrx2540 .................................................. 18 
3.2  Lifespan Analysis of Flies Expressing dPrx6 in an AD Background ............. 24 
3.3  Neuroinflammation in Flies Expressing Aβ or dPrx2540 .............................. 36 
3.4  Mutation of dPrx2540 Active Sites ............................................................... 45 
4.  DISCUSSION .............................................................................................................. 46 






LIST OF FIGURES 
 
2.1  Maps of the pCFD3 and pCFD4 plasmids .............................................................................. 15 
2.2  Map of pUASTattB plasmid ................................................................................................... 17 
3.1  Map of Drosophila chromosome 2 containing dPrx2540 ...................................................... 19 
3.2  PCR confirmation of deletion of all three copies of dPrx2540 .............................................. 20 
3.3  Western blot confirmation of deletion of all three copies of dPrx2540 ................................. 20 
3.4  Fertility assay comparing 2540null and yw flies .................................................................... 21 
3.5  Survivorship graphs of 2540null flies compared to the yw background ................................ 22 
3.6  Possible compensation of dPrx2540 protein expression in Δ2540-2 ...................................... 23 
3.7  Western blot quantification of dPrx6005 expression .............................................................. 25 
3.8  Western blot quantification of dPrx2540 expression .............................................................. 26 
3.9  Survivorship graphs of dPrx6005 expressing flies ................................................................. 28 
3.10  Survivorship graphs of dPrx2540 expressing flies (Male) ................................................... 31 
3.11  Survivorship graphs of dPrx2540 expressing flies (Female) ................................................ 33 
3.12  dPrx2540 Expression in 2x ELAV > dPrx2540 Flies ........................................................... 38 




3.14  AMP expression data from dPrx2540 over-expressors (Female) ......................................... 40 
3.15  AMP expression data from Aβ42 expressing flies (Aβ33773) .............................................. 42 
3.16  AMP expression data from Aβ42 expressing flies (Aβ33774) .............................................. 43 




LIST OF TABLES 
 
2.1  Genotype Abbreviations and Descriptions .............................................................................. 8 
3.1  Comparison of Survivorship Curves (dPrx6005) ................................................................... 29 
3.2  Comparison of Survivorship Curves (dPrx2540, Males) ....................................................... 32 






 I would like to thank Dr. William Orr granting me the opportunity to study at SMU and 
for his invaluable guidance throughout this project.  I also owe much to Nathan Drolet who 
taught me a great deal about lab work, especially during my first year.  Dr. Vladimir Klichko and 
Dr. Svetlana Radyuk have provided critical advice and instruction.  Thank you to my other 
committee members: Dr. Adam Norris and Dr. Pia Vogel.  Judith Benes has been a cornerstone 
of this project, maintaining the fly lab, assisting in experiments, and as another source of 
indispensable advice.  The assistance of the many undergraduates in the Orr lab has been vital to 
my success and the success of this project.  With special thanks to Sarah, Anh, Bronson, and 














Alzheimer’s Disease (AD) is the sixth leading cause of death in the United States and is 
the most common cause of dementia among older adults.  Current treatments focus on managing 
and, hopefully, retarding the symptoms of the disease.  However, the successful treatment of the 
cellular and molecular processes underlying this disease is still out of reach.  AD pathology is 
characterized by extra cellular plaques of the protein amyloid-β42 (Aβ42), Aβ42 oligomers, and 
neurofibrillary tangles of hyperphosphorylated Tau.  Such pathology tends to start in the 
hippocampus and cortex, but slowly spreads throughout the brain as the disease progresses.  The 
toxic protein aggregates impair the normal cellular processes of the affected neurons, leading to 
the characteristic neurodegeneration.  Patients develop dementia and sometimes physical 
impairments.  Death from Alzheimer’s is often a result of complications induced by increasing 
systemic dysfunction [Alzheimer's Disease Fact Sheet, 2019]. 
In the current model, extra-cellular Aβ42 plaques may actually serve a protective function 
while the Aβ42 oligomers are thought to be a cause of toxicity [Castellani et al., 2009].  Tau, 
which normally binds to microtubules, mislocalizes when hyperphosphorylated, forming tangles 
and impeding cellular transport, especially in dendritic spines [Hoover et al., 2010].  These 




proteins bind to pattern recognition receptors on glial cells, thus triggering an innate immune 
response including the release of inflammatory factors, including tumor necrosis factor-α (TNF-
α) [Heneka et al., 2015].  Inflammation and protein aggregates lead to elevated oxidative stress 
(OS), including peroxidized lipids.  In turn, such OS can promote further Aβ42 deposition and 
hyperphosphorylation of Tau.  It is likely that these factors play a key role in driving the 
neurodegeneration associated with Alzheimer’s and similar diseases [Chen and Zhong, 2014].   
Peroxiredoxins (Prx or Prdx) are ubiquitous regulators of reactive oxygen species (ROS), 
reducing peroxides and some reactive nitrogen species via thiol groups (-SH) of highly 
conserved catalytic cysteine residues, sometimes known as peroxidatic cysteines (CP).  As Prxs 
reduce peroxides, their CP is oxidized, which contributes to regulating their structure and 
secondary functions.  Therefore, Prxs can sense and react to changes in cellular redox state to 
drive various response pathways.  Peroxiredoxins are subdivided into three general classes: (1) 
typical 2-Cys, (2) atypical 2-Cys, and (3) 1-Cys Prxs.  All have a CP, while 2-Cys Prxs also have 
a resolving cysteine (CR) residue that is responsible for reducing the CP, either in the same 
molecule (atypical), or in another Prx subunit (typical) [Ahn et al., 2018].  The CP of a 1-Cys Prx 
is typically reduced by glutathione [Fisher, 2018].   
Peroxiredoxin 6 (Prx6) is a 1-Cys Prx and localizes to both cytosol and lysosomes 
[Sorokina et al., 2009].  However, it is perhaps primarily important for its unique functions 
including, the ability to bind phospholipids, reduce phospholipid peroxides (PRX activity), 
intracellular phospholipase activity (aiPLA2), and the transfer of fatty acyl CoA into the sn-2 
position of lysophosphatidylcholine (LPCAT activity) [Fisher, 2018].  Importantly for AD, Prx6 
is upregulated in the brains of patients, concentrated primarily in astrocytes, with smaller 




peroxiredoxins has been linked to improved stress resistance and lifespan, probably due 
primarily to their antioxidant functions, over-expression of Prx6 has been shown to exacerbate 
AD symptoms in mice [Radyuk and Orr, 2018] [Yun et al., 2013]. 
The PLA2 activity of Prx6 hydrolyzes the sn-2 fatty acyl bond of phospholipids, releasing 
arachidonic acid, a precursor to pro-inflammatory eicosanoids, such as prostaglandins and 
leukotrienes [Dennis, 1994] [Saul et al., 2019].  The Prx6 PLA2 active site consists of a catalytic 
triad of serine, histidine, and aspartate.  Interestingly, secreted PLA2 (sPLA2) enzymes are 
important in the mammalian inflammatory response and have been found in venoms from 
several taxa, including insects, arachnids, and reptiles [Nicolas et al., 1997].  With both PRX and 
PLA2 activities, Prx6 seems to have a role in regulating inflammation in response to oxidative 
damage to lipids.  Although, PLA2 activity has been implicated in exacerbating 




At an axis point between OS and inflammation, Prx6 may have valuable therapeutic 
potential for treating AD.  With the available information about Prx6 it may be that, in an AD 
background, the PLA2 activity drives inflammation, resulting in increased deposition of protein 
aggregates, exacerbating the AD phenotype, which further increases OS, causing upregulation of 
Prx6 and thus, more PLA2 activity.   
Drosophila melanogaster, which are being used as a model organism in this study, 




functions of human Prx6, while dPrx6005 lacks a PLA2 catalytic site.  Therefore, Drosophila are 
especially well equipped for testing the effects of Prx6 PLA2 activity against an AD background.  
Given this, our hypothesis is that when dPrx2540 (with PRX and PLA2 activity) is overexpressed 
in neurons of flies expressing human Aβ42, the AD phenotype should be exacerbated, including 
reduced lifespan, reduced activity, impaired learning and memory, and increased neuronal 
inflammation.  Under-expression of dPrx2540 in the AD fly model should somewhat alleviate 
the AD phenotype.  Over-expression of dPrx6005 (PRX activity only), or dPrx2540 with PLA2 
activity ablated, in neurons of flies expressing human Aβ42 should have a positive effect, due to 




The experiments performed for this project fall under two major objectives.  The first 
objective is to determine whether dPrx2540 or dPrx6005 have an effect on the AD phenotype in 
Drosophila.  This involves experiments to test survivorship, learning and memory, physical 
activity, and neuronal inflammation.  The AD background phenotype was generated by tissue 
specific expression of a human Aβ42 transgene in neurons. These experiments compare flies 
over-expressing or under-expressing, either dPrx2540 or dPrx6005, with and without the Aβ42 
background.  My contribution to this objective included confirmation of dPrx6 transgene levels 
by immunoblot analysis, survivorship studies, and the assessment of inflammation via qPCR. 
 The second major objective is to determine whether the PRX or PLA2 activity of 




methodology was used to delete all endogenous copies of dPrx2540, creating a “clean slate” 
Drosophila line with no Prx6 PLA2 activity.  Three dPrx2540 mutant lines were generated 
concurrently, one with an ablated PLA2 active site, one with an ablated PRX active site, and a 
third in which both PLA2 and PRX have been ablated.  The plan from here is to cross the 
different mutant transgenes into the dPrx2540-null Aβ42 background in order to directly test the 










2.1 The Gal4-UAS System and Experimental Crosses 
The Gal4-UAS system was adapted from yeast and provides a powerful tool for 
controlling tissue specific expression of a transgene in Drosophila.  Gal4 is a transcription factor 
that binds to UAS elements to induce transcription at the downstream start site.  A Gal4 driver 
construct consists of a Gal4 gene under control of a tissue specific promoter.  The target 
construct consists of a UAS-element upstream of the transgene we are interested in expressing 
[Chow, 2017].  The driver constructs used for this project were inserted into a Drosophila 
chromosome via P-element plasmids to make the “driver line”.  The target constructs were 
inserted in a similar manner into a separate “target line.”  Both driver and target lines have been 
generated from the same yellow-white (yw) Drosophila background line.  The transgene of 
interest, such as dPrx2540 or human Aβ42, will not be expressed until the driver line is crossed to 
the target line.  The progeny of this experimental cross will express any UAS-element transgenes 
present in its genome.  It is also important that the Gal4-UAS system is temperature sensitive, 
allowing another level of control over transgene expression.  Higher temperatures cause an 
increase in Gal4 activity [Brand et al., 1994]. 
Driver and target lines were raised separately in standard agar food bottles with 5mL/L 




without directly influencing the health of the experimental flies.  These flies were 
collected and females from the driver line were crossed with males from the target line.  Control 
crosses (transgene x yw and driver x yw) corresponding to each experimental cross (transgene x 
driver) were also made to account for any effects from transgene insertion.  The progeny 
generated from these crosses are the experimental flies, which are collected into fresh food vials 
with standard agar food.  All experimental crosses and offspring were raised at 28oC to enhance 
transgene expression.  Specific drivers and transgenes will be detailed for each experiment.   
 
 
2.2 Transgenic Drosophila Lines 
Table 2.1 contains a list and descriptions of the fly lines used for this project.  These fly 
lines were generated by P-element based insertion of UAS-transgenes.  Lines Aβ33773 and 
Aβ33774 were purchased from the Bloomington Drosophila Stock Center.  Line Aβ159 was 
generated at the Crowther lab at the University of Cambridge.  Lines containing constructs for 








This is the genetic background of the fly lines used for this project. 
ELAV 
Carries the Gal4 driver for neuronal expression. 
Located on the X chromosome. 
Aβ33773 
Carries the UAS-transgene for expression of human Aβ42 (no driver). 
Located on the 2nd chromosome. 
Aβ33774 
Carries the UAS-transgene for expression of human Aβ42 (no driver). 
Located on the 3rd chromosome. 
Aβ159 
Carries the UAS-transgene for expression of human Aβ42 (no driver). 
Located on the 2nd chromosome (different insertion from Aβ33773). 
dPrx6005 Carries the UAS-transgene for over-expression of dPrx6005 (no driver). 
RNAi-dPrx6005 Carries the UAS-transgene for RNAi knockdown of dPrx6005 (no driver). 
dPrx6005 + 
Aβ33773 
A combination line carrying two UAS-transgenes.  One for over-
expression of dPrx6005 and another for expression of Aβ42 (no driver). 
RNAi-dPrx6005 
+ Aβ33774 
A combination line carrying two UAS-transgenes.  One for under-
expression of dPrx6005 and another for expression of Aβ42 (no driver). 
dPrx2540 Carries the UAS-transgene for over-expression of dPrx2540 (no driver). 
RNAi-dPrx2540 Carries the UAS-transgene for RNAi knockdown of dPrx2540 (no driver). 
dPrx2540 + 
Aβ33773 
A combination line carrying two UAS-transgenes.  One for over-
expression of dPrx2540 and another for expression of Aβ42 (no driver). 
RNAi- dPrx2540 
+ Aβ33774 
A combination line carrying two UAS-transgenes.  One for under-
expression of dPrx2540 and another for expression of Aβ42 (no driver). 
Driver A > 
UAS-transgene 
X 
Indicates flies with both the indicated driver and indicated transgene, thus 
driving expression of the transgene.  For example, ELAV > dPrx2540 
flies are expressing the UAS-dPrx2540 transgene and should have higher 
levels of dPrx2540 protein than control flies. 
2540null 
Flies in which all three endogenous copies of dPrx2540 have been 
removed via CRISPR. 
 








2.3 Protein Isolation and Western Blots 
 Expression of dPrx2540 and dPrx6005 was measured by immunoblot analysis.  Flies 
were collected in 1.7mL micro-centrifuge tubes.  Protein isolation was done with either 20-30 
whole flies or 100-150 fly heads (whether whole flies or heads were used will be specified for 
individual experiments).  Fly tissue was homogenized in lysis buffer (10µL/fly, with EDTA and 
protease inhibitors) by grinding with a powered pestle in the centrifuge collection tube.  
Homogenates were centrifuged for 5 minutes at 12,000g, 4oC.  The supernatant was then 
transferred to a fresh centrifuge tube.  An equal volume of 2X β-mercaptoethanol loading dye 
was added to the supernatant and the sample was boiled for 3 minutes.  Protein concentrations 
were measured via Lowry assay on a UV-1800 Spectrophotometer (Shimadzu).  The Lowry 
assay was performed using the Bio-Rad DC Protein Assay reagents and recommended protocol. 
 For the Western Blot assays, equal amounts of total protein for each sample were run 
through 13% polyacrylamide gels before being transferred to a nitrocellulose membrane.  Next, 
the membranes were washed in a blocking solution of PBS-T and reconstituted milk.  After 
blocking, the membranes were washed again in the same blocking solution with primary 
antibodies for either dPrx2540 or dPrx6005, as well as primary antibodies for actin.  After 
treatment with primary antibodies, the membranes were washed in PBS-T, then washed again 
with blocking solution and horse radish peroxidase conjugated secondary antibodies.  Excess 
antibodies were washed off with PBS-T and the membranes incubated with ECL Western Blot 
Prime Detection reagents (GeneSee Scientific) to generate the chemiluminescent reaction.  The 
chemiluminescence was viewed and photographed with the Bio-Rad ChemiDoc Touch Imaging 
System.  Protein band intensity was quantified with Bio-Rad Image Lab v5.2.1.  Microsoft Excel 




control samples.  Primary antibodies used: mouse anti-actin C4 (1:2,500), rabbit anti-dPrx2540 
(1:5,000), rabbit anti-dPrx6005 (1:2,500).  Secondary antibodies used: HRP-conjugated anti-
mouse (1:20,000) and HRP-conjugated anti-rabbit (1:20,000). 
 Before protein or RNA isolation procedures, fly heads were collected from experimental 
cohorts of 100-200 flies.  Typically, 100 heads are enough for protein samples, but for RNA 
isolation, starting with 200 flies is useful for isolation of much more concentrated samples.  The 
sample flies were collected and transferred to a 15mL graduated plastic tube which was then 
dipped in liquid nitrogen and shaken to separate heads, wings and legs, and thoraces/abdomens.  
After several successive freeze/shake cycles, the fly pieces are sifted through a three-part sieve.  
The top level (0.71mm) held thoraces/abdomens, the middle level (0.5mm) caught the heads, and 
the waste collection bowl at the bottom caught the wings and legs.  The heads were transferred 
from the middle 0.5mm sieve to a 1.7mL microcentrifuge tube for later processing.  The liquid 
nitrogen was also used to keep the flies, sieve, and sample tubes as cold as possible through this 




2.4 RNA Isolation and qPCR 
RNA was isolated from fly heads using the TRIzol Reagent protocol (Ambion, Inc.), 
200µL TRIzol/150 fly heads.  RNA samples were assayed for concentration with a UV-1800 
Spectrophotometer (Shimadzu).  These samples were reverse transcribed (RT) using the 




All RT samples in a given experiment started with a uniform amount of RNA, usually 4-
6µg/30µL RT reaction, depending on the sample with lowest concentration.  DNase treatment 
(optional with ThermoFisher’s Master Mix) was done on the first set of samples.  However, such 
DNase treatment was suspended because optimization tests revealed that, when performed 
carefully, the above protocols did not introduce significant DNA contamination and qPCR was 
more efficient without the optional treatment.  Each qPCR run includes a negative RT control 
using Maxima H Minus no RT Master Mix (included with the kit from ThermoFisher) for each 
cDNA sample to ensure that there was no significant DNA contamination. 
qPCR was performed with the GoTaq qPCR Master Mix (Promega) and primers specific 
to each AMP.  Primers specific for RP49 were used to provide a positive reaction control from 
which to normalize total mRNA.  For each cDNA-primer combination, experimental reactions 
were prepared as three 18µL technical replicates.  qPCR reactions were run on a Rotor-Gene 
3000 thermal cycler (Corbett Research).  The cycling program heated the samples to 95oC for 30 
seconds, down to 50oC for 30 seconds, and up to 72oC for 30 seconds, repeated for 39 cycles. 
 
 
2.5 DNA Isolation, PCR, and Electrophoresis 
 DNA was isolated from samples of 5-30 whole flies, depending on how many were 
available from a given cross or experiment.  Protocols and materials were from either the Quick-
DNA Universal kit (Zymo Research) or QuickDNA MiniPrep Plus kit (Zymo Research).  DNA 
concentration was measure with a UV-1800 spectrophotometer (Shimadzu) to ensure an 




 Analytical PCR reaction mixes contained 5µL GoTaq Hot Start Master Mix (Promega), 
0.5µL each of 10mM forward and reverse primers, 1-2µL of DNA template, and filled to 10µL 
total volume with nuclease-free water.  A Mastercycler Personal (Eppendorf) thermal cycler was 
used for the PCR run with 31 cycles.  Annealing temperatures were adjusted for optimal primer 
conditions and extensions times adjusted to account for expected product length. 
 Electrophoresis gels were made with 0.5X TAE buffer, 1.4% agarose, and ethidium 
bromide.  The TAE buffer was diluted from a 10X stock made with 48.4g Tris base, 11.4mL 
glacial acetic acid, 3.7g of EDTA, then filled to 1L with MilliQ water.  The RunOne 
Electrophoresis Cell (EmbiTec) was filled with 0.5X TAE buffer and about 1µL of extra 
ethidium bromide to ensure that DNA bands would be easily visible.  A DNA molecular weight 
ladder was run beside samples to measure band sizes.  Either ECON RCR DNA Ladder (Apex) 
or the 1kb DNA Ladder (GibcoBRL) were used for the ladder.  The electrophoresis was 
generally run at 100 volts and a ChemiDoc Touch Imaging System (Bio-Rad) was used to 
acquire images of the results. 
 
 
2.6 Lifespan Experiments 
 For all lifespan analyses, experimental flies were raised at 28oC and collected into food 
vials (25 flies/vial) under CO2-induced anesthesia.  Each experimental condition and 
corresponding controls started with a total of 125 flies in 5 vials.  Throughout the experiment the 
28oC temperature and 12h light/12h dark (08:00 to 20:00) cycle was maintained.  Flies were 




flies was recorded, and the dead flies were removed.  Mortality tracking data was entered into 




2.7 Fertility Assay 
The fertility assay was performed by pair mating age-matched virgin flies.  yw males 
were mated to yw females and similarly, 2540null males mated to 2540null females.  Each 
replicate consisted of one male and one female placed into a standard food vial.  Twenty 
replicates of each condition were generated and kept at 25oC with a 12h light/12h dark (08:00 to 
20:00) cycle.  Every day, each mated pair was transferred to a fresh food vial to help prevent 
overcrowding of offspring.  As they began eclosing, the offspring of each mated pair were 





 The plasmid pCFD3 (Figure 2.1, top) was used to insert the gRNA for deletion of 
dPrx2540-1 and dPrx2540-3.  dPrx2540-3 is located just downstream of dPrx2540-1, running in 
the opposite direction.  The single gRNA (sequence: ATCAAACAGCAAGATGCGTTTGG) 




oligonucleotide was ligated into pCFD3 between the dU6-3 promoter and the gRNA scaffold.  
The pCFD4 plasmid (Figure 2.1, bottom) was used to insert the two gRNAs targeting sequences 
upstream and downstream of dPrx2540-2 (upstream: AACGTGATCGACGTAAATAG) 
(downstream: GAATGGATCACAAATGGGGAA).  The first gRNA oligonucleotide was 
ligated into pCFD4 between the dU6-1 promoter and the corresponding gRNA scaffold.  The 
second gRNA oligonucleotide was ligated into pCFD4 between the dU6-3 promoter and 
corresponding gRNA scaffold.  Plasmids were sent to Retrogen, Inc. for sequencing to confirm 
insertion of the gRNAs, then sent to BestGene, Inc. for injection into Drosophila embryos.  Flies 
expressing the gRNAs were crossed with flies expressing a Cas9 transgene under the control of 











2.9 Molecular Cloning 
 The DNA fragment to be used for cloning, such as dPrx2540, was amplified via PCR 
using the Q5 High-Fidelity 2X Master Mix (New England Biolabs).  The amplified fragment was 
isolated from a sterilized agarose gel and purified using the QIAquick Gel Extraction Kit 
(Qiagen).  Restriction digestion of the pUAST plasmid (Figure 2.2) was done with FastDigest 
BglII and FastDigest XhoI in 10X FastDigest Buffer (ThermoFisher) using the recommended 
protocol from ThermoFisher.  The desired plasmid fragments were then extracted from agarose 
gels as mentioned above.  Ligation of DNA fragment into the plasmid was done with T4 DNA 
Ligase, 10X T4 DNA Ligase Buffer, and T4 polynucleotide kinase from New England Biolabs 
using their recommended protocol [New England Biolabs, 2019].  Plasmids were then 
transformed into DH5α E. coli via heat shock at 42oC for 30 seconds to encourage plasmid 
uptake.  Afterwards, the E. coli were incubated in SOC media and plated onto ampicillin 
(100mg/mL) LB agar.  Transformed colonies were selected for ampicillin resistance, then re-
streaked on ampicillin LB agar.  Clonal colonies were tested by PCR for the presence of the 
plasmid containing the desired transgene construct.  Large scale cultures for plasmid 
preparations were grown in LB liquid media.  Plasmids were sent to GeneWiz for sequencing to 






Figure 2.2.  Map of the pUASTattB plasmid used as the insertion vector for UAS-dPrx2540, 
UAS-dPrx6005, and UAS-dPrx2540 mutant transgenes.  cDNA for the desired gene was ligated 








3.1 CRISPR Deletion of Endogenous dPrx2540 
 Drosophila have three copies of dPrx2540 (dPrx2540-1, -2, -3) clustered together on 
chromosome 2.  However, there are two putative genes located between dPrx2540-2 and 
dPrx2540-1/3, so all three copies could not be removed at once [Thurmond et al. 2019].  Instead, 
the deletion was done in two stages.  First, dPrx2540-2 was deleted by crossing flies expressing 
nos-Cas9 (germline expression) with flies expressing gRNAs flanking dPrx2540-2 (Figure 3.1).   
Germline expression of Cas9 causes the target locus to be deleted only in the germline of 
the F1 generation, then the F2 generation carries the deletion in all cells.  Pair mating was used to 
cross the F1 generation with glazed/CyO mutant flies for screening and tracking of the deletion.  
300 pair matings were done for the deletion of dPrx2540-2 due to the expectation of low 
efficiency.  5 of these 300 pair matings produced offspring carrying the deletion (hereafter 
Δ2540-2).  Second, nos-Cas9 expressing flies were crossed with flies expressing gRNAs (in the 





Figure 3.1.  FlyBase map of the region of Drosophila chromosome 2 containing the three copies 
of dPrx2540 [Thurmond et al. 2019].  The blue box and blue arrows indicate gRNA target sites 
for deletion of dPrx2540-2.  The red box and red arrows indicate gRNA target sites for deletion 
of dPrx2540-1/3. 
 
For the second deletion, a total of 600 pair matings produced two lines carrying the 
Δ2540-1/-3 deletion.  The deletions were screened with PCR (Figure 3.2) and confirmed by 
sequencing performed by GeneWiz (not shown).  The deletion of all 3 copies of dPrx2540 
(hereafter 2540null) was further confirmed by western blot to ensure no endogenous production 






Figure 3.2.  PCR confirmation of deletion of all three copies of dPrx2540.  No amplification is 
seen from any of the three primer sets for the 2540null-269B cohort.  A relatively strong band 
appears with both sets of dPrx2540-1/3 primers in the 269A cohort, indicating contamination in 




                          
Figure 3.3.  Western blot confirmation of the deletion of all endogenous dPrx2540 genes.  The 






To characterize the 2540null phenotype, lifespan and fertility assays are being performed, 
comparing 2540null flies to the yw background from which they were generated.  Though, still in 
progress, the fertility assay reveals a significant reduction in offspring produced by 2540null flies 
compared to the yw background (Figure 3.4).  Ongoing survivorship experiments show a 
significant reduction in the lifespan of 2540null flies compared to yw for both males and females 
(Figure 3.5).  It is somewhat expected that 2540null flies would have impaired health given the 
reported function for Prx6 in peroxidized membrane repair [Fisher, 2017].  Lipid peroxidation 




Figure 3.4.  Fertility assay comparing 2540null and yw flies.   Each point indicates the average 
offspring produced on a particular day across all replicates.  Error bars indicate standard 
deviation between replicates.  Black = yw control.  Red = 2540null.  P values were calculated 











Figure 3.5.  Survivorship graphs of 2540null flies compared to the yw background.  Red = 
2540null.  Black= yw.  P values were calculated using the log-rank (Mantel-Cox) test. 
 
 
Interestingly, Drosophila may have a compensatory mechanism for expression of dPrx6.  
Between the three copies of dprx2540, dPrx2540-2 has the highest reported expression 
[Thurmond et al., 2019].  Yet, flies with dPrx2540-2 deleted from their genome, showed no 








Figure 3.6.  Possible compensation of dPrx2540 protein expression in Δ2540-2 flies.  The graph 
shows the quantification of two western blots testing expression of dPrx2540 in three Drosophila 
lines in which dPrx2540-2 was successfully removed via CRISPR.  There is no significant and 
consistent change in dPrx2540 expression due to the deletion.  Error bars indicate standard 





3.2 Lifespan Analysis of Flies Expressing dPrx6 in an AD Background 
 As discussed in Chapter 1.3, AD causes several symptoms in humans that can be 
measured in a Drosophila model of AD.  Flies expressing transgenic constructs of human 
“arctic” Aβ42 experience neurodegeneration and early death, reducing their average lifespan by 
half or more [Crowther et al., 2005].  If PLA2 activity exacerbates AD symptoms as expected, 
overexpressing dPrx2540 (with PLA2 activity) in flies also expressing Aβ42 (the AD background) 
should result in a further decrease in lifespan.  Conversely, under-expressing dPrx2540 in the AD 
background flies should have an opposite effect, extending their lifespan.  Over-expression of 
dPrx6005 (without PLA2 activity) should have little effect on the AD background or possibly 
even a beneficial effect from the PRX activity reducing OS. 
 For the lifespan experiments, combination AD + dPrx2540 lines with the highest (over-
expressor) or lowest (under-expressor) dPrx2540 expression were selected for the experimental 
crosses.  Transgenic line UAS-Aβ33773, over.2540 B1 (hereafter shown as dPrx2540 + 
Aβ33773) was chosen for over-expression in the AD background and line UAS-Aβ33774, 
RNAi-2540-8ds A1 (hereafter shown as RNAi-dPrx2540 + Aβ33774) was chosen for under-
expression in the AD background.  ELAV-Gal4 (hereafter shown as ELAV) was chosen as the 
driver because it drives transgene expression specifically in neurons.  Transgenic lines were 
crossed to ELAV lines to generate experimental flies (ELAV > dPrx2540 + Aβ33773 or ELAV > 
RNAi-dPrx2540 + Aβ33774) or crossed to yw to generate control lines.  Transgenic lines 
expressing only Aβ33773 or Aβ33774 (ELAV > Aβ33773 or ELAV > Aβ33774), were also 
generated to create the AD background for comparison.  Two separate lifespan experiments have 
been performed to examine the effect of dPrx2540 expression against an AD background.  In the 




against an AD background.  The relative expression of dPrx6005 in experimental and control 




Figure 3.7.  Western blot quantification of dPrx6005 expression in fly heads. These fly lines 
were used for the lifespan assay to determine the effect of dPrx6005 expression on the AD 
background.  Expression is shown relative to ELAV (driver only) and normalized to actin.  Grey 
bars = control lines.  Black bar = ELAV control. Red bars = dPrx6005 over-expression lines.  







Figure 3.8.  Western blot quantification of dPrx2540 expression in fly heads. These fly lines 
were used for the lifespan assay to determine the effect of dPrx2540 expression on the AD 
background.  Expression is shown relative to ELAV (driver only) and normalized to actin.  Grey 
bars = control lines.  Black bar = ELAV control. Red bars = dPrx2540 over-expression lines.  






Male flies overexpressing dprx6005 in the AD background (ELAV > dPrx6005 + 
Aβ33773) showed no significant change in lifespan compared to the AD background alone 
(ELAV > Aβ33773).  Somewhat unexpectedly, males under-expressing dPrx6005 in the AD 
background (ELAV > RNAi-dPrx6005 + Aβ33774) showed a significant increase in lifespan 
compared to the AD background alone (ELAV > Aβ33774) (Figure 3.9, top panels and Table 
3.1).  Female flies overexpressing dPrx6005 in the AD background show a significant increase in 
lifespan compared to the AD background (Figure 3.9, bottom panels and Table 3.1).  Female 
flies under-expressing dPrx6005 in the AD background also showed a significant increase in 
lifespan compared to the AD background.  Interestingly, the increase in lifespan due to under-
expression of dPrx6005 appears to be larger than that resulting from over-expression of 
dPrx6005, though both comparisons to the AD background share the same p-value (Figure 3.9, 
bottom panels and Table 3.1).  ELAV > dPrx6005 median lifespan was similar to the yw genetic 
background and greater than ELAV alone, thus over-expression of dPrx6005 alone seems to 
have little to no effect on fly lifespan (data not shown).  ELAV > RNAi-dPrx6005 median 
lifespan was greater than all other experimental and control lines for males and females (data not 
shown).  Suppressing expression of dPrx6005 had a beneficial effect with and without Aβ42 
expression.  PRX activity in some other peroxiredoxins is known to be beneficial, extending 
lifespan and enhancing oxidative stress resistance [Radyuk and Orr, 2018], so it is puzzling that a 























Figure 3.9.  Survivorship graphs of flies comparing the effects of dPrx6005 expression in the 
AD background.  Top panels show data from males.  Bottom panels show data from females.  
After experimental crosses, all flies had a single copy of the ELAV driver and a single copy of 
each UAS-transgene.  Asterisks indicate significant differences (see Table 3.1). 
  
In the first lifespan experiment to analyze the effects of dPrx2540 expression (Figure 
3.10, top panels and Table 3.2), male flies overexpressing dPrx2540 in the AD background 
(ELAV > dPrx2540 + Aβ33773) did not display a significant change in lifespan compared to 
flies expressing Aβ42 alone (ELAV > Aβ33773).  This seems to be contrary to the working 
hypothesis that dPrx2540 should exacerbate the AD phenotype.  However, males under-
expressing dPrx2540 in the AD background (ELAV > RNAi-dPrx2540 + Aβ33774) showed an 
increase in median lifespan as well as a large increase in maximum lifespan compared to flies 
expressing Aβ42 alone (ELAV > Aβ33774).  Males under-expressing dPrx2540 alone, without 













P Value (effect) 
 
Compared to 
ELAV > Aβ33773 12   
ELAV > dPrx6005 + Aβ33773 11 0.2 (ND) ELAV > Aβ33773 
Control 41   
ELAV > dPrx6005 37 0.0371 (decrease) Control 







P Value (effect) 
 
Compared to 
ELAV > Aβ33773 22   
ELAV > dPrx6005 + Aβ33773 24 0.0001 (increase) ELAV > Aβ33773 
Control 41   
ELAV > dPrx6005 45 0.0003 (increase) Control 
    









P Value (effect) 
 
Compared to 
ELAV > Aβ33774 17   
ELAV > RNAi-dPrx6005 + 
Aβ33774 
18 0.0001 (increase) ELAV > Aβ33774 
Control 36   
ELAV > RNAi-dPrx6005 43 0.0001 (increase) Control 
  






P Value (effect) 
 
Compared to 
ELAV > Aβ33774 26   
ELAV > RNAi-dPrx6005 + 
Aβ33774 
32 0.0001 (increase) ELAV > Aβ33774 
Control 44   
ELAV > RNAi-dPrx6005 52 0.0001 (increase) Control 
  
 
Table 3.1. Comparison of survivorship curves for flies expressing dPrx6005 in an AD 
background.  P values were calculated using the log-rank (Mantel-Cox) test.  Effects listed in 






The second experiment with dPrx2540 yielded slightly different results (Figure 3.10, 
bottom panels and Table 3.2).  Males overexpressing dPrx2540 in the AD background showed a 
significant increase in median lifespan compared to the AD background line, which was not 
consistent with the first experiment.  As in the first experiment, ELAV > RNAi-dPrx2540 + 
Aβ33774 produced a beneficial effect on median lifespan compared to ELAV > Aβ33774.  
Again, knocking down dPrx2540 in the absence of Aβ33774 actually reduced median lifespan 
compared to the control, which may be important given the nascent results in the lifespan assay 
with the 2540null flies (Figure 3.5). There seemed to be a trend towards an increase in maximum 
lifespan in males under-expressing dPrx2540 in the AD background compared to the AD 
background alone, though this was reversed in the last surviving 10% due to a few strangely 
long-lived flies despite expression of Aβ42.  It is notable that under-expression of dPrx2540 or 
dPrx6005 produced a larger increase in lifespan in males. 
Interestingly, despite strong positive effects on lifespan from over- and under-expression 
of dPr6005, female flies showed much weaker effects from over- and under-expression of 
dPrx2540 in the AD background compared to the results with male flies (Figure 3.11 and Table 
3.3).  In the first experiment analyzing the effects of dPrx2540 expression, female flies of ELAV 
> dPrx2540 + Aβ33773 showed no change in lifespan compared to the ELAV > Aβ33773.  
Female flies of ELAV > RNAi-dPrx2540 + Aβ33774 had a large increase in median lifespan and 
maximum lifespan when compared to ELAV > Aβ33774.  For female flies, the repeat of this 
experiment gave less consistent results than those seen with males.  ELAV > dPrx2540 + 
Aβ33773 showed a mild, but significant, increase in median lifespan, while ELAV > RNAi-



































   
 
Figure 3.10.  Survivorship graphs of male flies comparing the effects of dPrx2540 expression in 
the AD background.  Data from two separate experiments are shown: (top) the 1st lifespan 
experiment testing the effects of dPrx2540 expression, and (bottom) repeat of the lifespan 
experiment testing the effects of dPrx2540 expression.  After experimental crosses, all flies had a 
single copy of the ELAV driver and a single copy of each UAS-transgene.  Asterisks indicate 














P Value (effect) 
 
Compared to 
ELAV > Aβ33773 14   
ELAV > dPrx2540 + Aβ33773 15 0.0091 (ND) ELAV > Aβ33773 
Control 40   
ELAV > dPrx2540 41 0.4106 (ND) Control 
    






P Value (effect) 
 
Compared to 
ELAV > Aβ33773 15   
ELAV > dPrx2540 + Aβ33773 16 0.0019 (increase) ELAV > Aβ33773 
Control 44.5   
ELAV > dPrx2540 47 0.2138 (ND) Control 
    









P Value (effect) 
 
Compared to 
ELAV > Aβ33774 17   
ELAV > RNAi-dPrx2540 + 
Aβ33774 
20 0.0001 (increase) ELAV > Aβ33774 
Control 40   
ELAV > RNAi-dPrx2540 37 0.3895 (decrease) Control 
  






P Value (effect) 
 
Compared to 
ELAV > Aβ33774 17   
ELAV > RNAi-dPrx2540 + 
Aβ33774 
21.5 0.0001 (increase) ELAV > Aβ33774 
Control 44.5   
ELAV > RNAi-dPrx2540 39 0.1111 (decrease) Control 
  
 
Table 3.2. Comparison of survivorship curves for male flies expressing dPrx2540 in an AD 
background.  P values were calculated using the log-rank (Mantel-Cox) test.  Effects listed in 




































   
 
Figure 3.11.  Survivorship graphs of female flies comparing the effects of dPrx2540 expression 
in the AD background.  Data from two separate experiments are shown: (top) the 1st lifespan 
experiment testing the effects of dPrx2540 expression, and (bottom) repeat of the lifespan 
experiment testing the effects of dPrx2540 expression.  After experimental crosses, all flies had a 
single copy of the ELAV driver and a single copy of each UAS-transgene.  Asterisks indicate 














P Value (effect) 
 
Compared to 
ELAV > Aβ33773 27   
ELAV > dPrx2540 + Aβ33773 25.5 0.1873 (ND) ELAV > Aβ33773 
Control 47   
ELAV > dPrx2540 49 0.005 (increase) Control 
    






P Value (effect) 
 
Compared to 
ELAV > Aβ33773 33   
ELAV > dPrx2540 + Aβ33773 31 0.0367 (ND) ELAV > Aβ33773 
Control 52   
ELAV > dPrx2540 48 0.0001 (decrease) Control 
    









P Value (effect) 
 
Compared to 
ELAV > Aβ33774 28   
ELAV > RNAi-dPrx2540 + 
Aβ33774 
36 0.0001 (increase) ELAV > Aβ33774 
Control 47   
ELAV > RNAi-dPrx2540 52 0.0001 (increase) Control 
  






P Value (effect) 
 
Compared to 
ELAV > Aβ33774 29   
ELAV > RNAi-dPrx2540 + 
Aβ33774 
30 0.9403 (ND) ELAV > Aβ33774 
Control 52   
ELAV > RNAi-dPrx2540 53 0.0298 (ND) Control 
  
 
Table 3.3. Comparison of survivorship curves for female flies expressing dPrx2540 in an AD 
background.  P values were calculated using the log-rank (Mantel-Cox) test.  Effects listed in 





The increase in lifespan due to over-expression of dPrx2540 could be explained by 
beneficial effects from the PRX activity, while the increase in lifespan due to under-expression 
of dPrx2540 could be explained by reduced PLA2 activity as predicted by the hypothesis.  
Considering the relatively weak over-expression of dPrx2540 seen in the western blots (Figure 
3.8), we reasoned that in order to observe the potential negative effects of PLA2, stronger over-
expression of dPrx2540 would need to be induced.  To this end, flies with two copies of the 
ELAV driver, two copies of the dPrx2540 over-expression construct, and one copy of Aβ33773 
were generated.  Generation of flies with two copies of Aβ33773 was attempted, but this 
combination proved to be lethal.  Two copies of the ELAV driver and two copies of Aβ33773 
without dPrx2540 was also lethal.  One copy of the AB33773 transgene should be enough 
because it is well established that this causes drastically shortened lifespan when expressed.  A 
lifespan experiment with large over-expression of dPrx2540 using these double driver/double 




3.3 Neuroinflammation in Flies Expressing Aβ or dPrx2540 
  In Drosophila, the innate immune response is primarily controlled by the NF-κB 
pathways, Toll and IMD [Govind, 2008].  Part of this inflammatory response involves 
antimicrobial peptides (AMPs), small peptides that kill invading bacteria and fungi.  Expression 
of these AMPs are induced through the Toll and IMD pathways.  The Toll pathway responds to 
infection by Gram positive bacteria and fungi by producing Drosomycin, Attacins, Cecropins, 
and Defensins.  The IMD pathway responds to infection by Gram negative bacteria by producing 
Diptericin, Attacins, and Cecropins [Imler and Bulet, 2005].  Expression of another innate 
defense factor, Turandot, is mediated by the JAK/STAT pathway in response to various stresses, 
such as infection, OS, and protein aggregates.  Critically, pattern recognition receptors (PRRs), 
including Toll-like receptors (TLRs), also respond to endogenous damage associated molecular 
patterns (DAMPs) such as the misfolded and mislocalized Aβ42 and Tau proteins that hallmark 
AD pathology [Morales et al., 2014].  Additionally, AD pathology has been reported to induce 
expression of TNF-α, a pro-inflammatory target of the NF-κB pathway, is also involved in 
activating apoptosis of damaged or infected cells [Heneka et al., 2015] [Wu and Zhou, 2010].  
The Drosophila homolog of TNF-α is known as Eiger.   
 The hypothesis states that dPrx2540 exacerbates AD by promoting neuroinflammation 
through its PLA2 activity.  To test this, expression levels of the Attacin C, Cecropin, Defensin, 
Diptericin, Drosomycin, Eiger, and Turandot were measured in fly heads, via qPCR, as markers 
of neuroinflammation.  These genes are expressed at very low levels in healthy cells, but 
expression increases dramatically with infection, loss of proteostasis, or age [Odnokoz et al., 
2017].  Experimental flies were prepared as described in Chapter 2.1 and aged for 10 or 15 days.  




positive results.  Each day, the experimental flies were transferred to fresh food vials to reduce 
the risk of infection due to bacterial growth. 
To test whether dPrx2540 expression alone could induce a neuroinflammatory response, 
the expression of five AMPs, Eiger, and Turandot was examined via qPCR in the heads of 10-
day old flies with two copies (2x) of both the ELAV driver and the dPrx2540 transgene (2x 
ELAV > dPrx2540).  In these lines ELAV drives neuronal expression of dPrx2540 to very high 
levels relative to controls (Figure 3.12).  As shown in Figures 3.13 (Males) and 3.14 (Females), 
the experimental lines with 2x ELAV > dPrx2540 (2) and (3) do not show the large increase in 
expression of inflammatory markers, compared to controls, that would indicate a positive result.  
This experiment was also done with 2x ELAV > dPrx2540 lines (4) and (15) and with APPL 
driven dPrx2540 expression.  APPL is the Drosophila ortholog of human APP, precursor to Aβ 
[Prüßing et al., 2013].  These additional experiments produced similar results (data not shown).  
Therefore, dPrx2540 over-expression alone, in neurons, does not appear to cause inflammation.  
The particular Drosophila AD model used for these experiments, directly expressing 
human Aβ42 from a UAS transgene, has been shown to cause early mortality in the experimental 
fly lines (see Chapter 3.2).  However, inflammation due to Aβ42 expression has not been 
confirmed in this AD model.  Therefore, AMP expression was also tested in 10 and 15-day old 
fly heads of the Aβ42 expressing Drosophila lines being used throughout this project.  Typically, 
male flies expressing Aβ42 begin dying in large numbers at ~10-15 days old, while controls tend 

















Figure 3.12.  dPrx2540 Expression in 2x ELAV > dPrx2540 Flies.  (A) Sample western blot 
showing dPrx2540 protein.  (B) Quantification for the western blot shown in (A).    (C) 
Quantification of dPrx2540 over-expression in lines (2) and (3).  AMP expression for these flies 
is shown in figures 3.13 and 3.14.  These experiments were conducted with 10-day old flies 
raised at 28oC.  Expression was calculated relative to the corresponding driver control (ELAV or 






















Figure 3.13.  Representative AMP expression data from 2x dPrx2540 over-expressors.  These 
graphs indicate the average fold-change in AMP expression relative to ELAV (driver only 
control) and normalized to RP49 (a housekeeping gene).  Expression was measured via qPCR. 
Error bars indicate standard deviation between three technical replicates.  The experiment was 
























Figure 3.14.  Representative AMP expression data from 2x dPrx2540 over-expressors.  These 
graphs indicate the average fold-change in AMP expression relative to ELAV (driver only 
control) and normalized to RP49 (a housekeeping gene).  Expression was measured via qPCR.  
Error bars indicate standard deviation between three technical replicates.  The experiment was 







The flies tested in this experiment had a single copy of the driver and transgenes, 
generated in the same manner as those used for the lifespan experiments shown in Figures 3.9 
and 3.10.  The UAS-Aβ33773 construct is located on the 2nd chromosome.  Expression of Aβ42 
from this construct did not induce the dramatic increase in AMP expression that would be 
indicative of inflammation (Figure 3.15).  The UAS-Aβ33774 construct is located on the 3rd 
chromosome and, again, expression of Aβ42 did not produce an increase in AMP expression 
(Figure 3.16).  Together, these data strongly suggest that expression of human Aβ42 alone, in 
neurons, does not induce neuroinflammation in Drosophila.   
ELAV > dPrx2540 + Aβ33773 was included to examine possible effects of dPrx2540 
over-expression on any inflammation caused by Aβ42 expression.  Without inflammation in the 
AD background, any additional effects caused by over-expression of dPrx2540 were 
indeterminate.  However, the dPrx2540 + Aβ33773 control (no driver) actually seems to induce 
expression of cecropin and diptericin.  ELAV > dPrx2540 + Aβ33773 also induces expression of 
cecropin and diptericin, but to a lesser degree (Figure 3.15).  This effect is not seen with ELAV 
alone (driver only) or Aβ33773 alone (transgene only).  These results were repeated alongside 
the experiments with ELAV > Aβ33774.  AMP expression was then tested in a different 
recombinant line, ELAV > dPrx2540 + Aβ33774, to determine if this effect was common to flies 
carrying transgenes for dPrx2540 and Aβ42 (Figure 3.17).  There was no increase in expression 
for cecropin or diptericin in the ELAV > dPrx2540 + Aβ33774 flies.  Therefore, it is possible 
that the particular recombination event that generated the dPrx2540 + Aβ33773 line disrupted 
other genes, resulting in elevated expression of cecropin and diptericin.  The lifespan of these 
flies is comparable to other controls such as yw and ELAV.  Overall, no strong inflammatory 





















Figure 3.15.  Representative AMP expression data from Aβ42 expressing flies.  These graphs 
indicate the average fold-change in AMP expression relative to ELAV (driver only control) and 
normalized to RP49 (a housekeeping gene).  Expression was measured via qPCR.  Error bars 
indicate standard deviation between three technical replicates.  The experiment was performed 





















Figure 3.16.  Representative AMP expression data from Aβ42 expressing flies.  These graphs 
indicate the average fold-change in AMP expression relative to ELAV (driver only control) and 
normalized to RP49 (a housekeeping gene). Expression was measured via qPCR.  Error bars 
indicate standard deviation between three technical replicates.  The experiment was performed 











Figure 3.17.  AMP expression data from flies expressing Aβ33774 + dPrx2540.  These graphs 
indicate the average fold-change in AMP expression relative to ELAV (driver only control) and 
normalized to RP49 (a housekeeping gene). Expression was measured via qPCR.  Error bars 
indicate standard deviation between three technical replicates.  The experiment was performed 




3.4 Mutation of dPrx2540 Active Sites 
 In order to determine more directly whether PRX or PLA2 activities of dPrx2540 are 
responsible for the effects of dPrx2540 expression in the AD background, mutations were made 
in dPrx2540 to inactivate the appropriate catalytic sites.  To ablate PRX activity, the C43S 
mutation was selected because it was a simple change that leaves a preferred codon for serine.  
The primer sequence for this mutation is TTACTCCCGTCTCCACCACTGAG, where the 
underlined “C” is a nucleotide mismatch to generate the point mutation.  To ablate PLA2 activity, 
the D135A mutation was selected because the mutation would leave a preferred codon for 
alanine and because mutating either H22 or S28 (of the PLA2 catalytic triad) would reportedly 
disrupt other functions of dPrx2540 as well [Fisher, 2018].  The primer sequence for this 
mutation is CATCAGTCCGGCCCATAAGGTGC, where the underlined “C” is a nucleotide 
mismatch to generate the point mutation.  Reverse compliment primers were made, and the 
mutagenesis proceeded via primer overlap extension PCR.  A double mutant was made by 
applying the primers for the PLA2 mutation to the completed PRX mutant.  The mutant 
constructs were ligated into the pUASTattB plasmid used to create the original dPrx2540 over-
expressors as discussed in Chapter 2.9.  Injection of the mutant constructs into the yw 
background and backcrossing of these flies has been completed.  These UAS-dPrx2540(ΔPRX) 
or (ΔPLA2) or double (ΔPRX + ΔPLA2) mutant flies are now being crossed into the 2540null 








Production of arachidonic acid via PLA2 activity is part of a known pro-inflammatory 
pathway [Reuters, 2019].  Because Prx6 has PLA2 function and is upregulated in AD patient 
brains, it is surmised that this enzyme could exacerbate AD symptoms by helping to drive the 
neuronal inflammatory response.  To test this, dPrx2540 of Drosophila, a homolog of human 
Prx6, was ectopically expressed or suppressed in a Drosophila model of AD that expresses 
human Aβ42.   
Data from the initial lifespan experiments with dPrx2540 suggests that under-expression 
of dPrx2540 is beneficial to survival.  Surprisingly, over-expression was also mildly beneficial, 
but the effect was less consistent than with under-expression.  Male flies also seemed to have 
more pronounced benefits than females.  The planned lifespan experiments with homozygous 
over-expressors of dPrx2540 may produce a stronger result that would help with interpretations 
of data.  Both over- and under-expression of dPrx6005 had beneficial longevity effects in 
females.  In males, over-expression of dPrx6005 had no significant impact on longevity whereas 
under-expression elicited negative effects in terms of early death, but beneficial longevity effects 
for the remaining flies.  However, this survivorship study was only conducted once and will need 




The expression of AMPs as markers of inflammation were measured because dPrx2540 is 
thought to activate pro-inflammatory pathways via production of arachidonic acid from its PLA2 
activity.  If PLA2 activity is responsible for causing inflammation, then a large increase in 
dPrx2540 expression would be expected to cause an upregulation in AMPs.  However, no 
significant inflammation was detected from four different dPrx2540 overexpressing lines, in 
either males or females.  With this unexpected result, the question became whether the 
Drosophila AD lines used in this project experienced neuroinflammation.  The lines Aβ33773 
and Aβ33774 are known to form Aβ42 plaques and have severely reduced lifespan, indicating 
that they have an AD phenotype.  When tested for inflammation via AMP expression, these AD 
lines also showed no detectable inflammatory response from fly heads.  In Drosophila, AMPs 
are produced in the fat bodies, including one in the head [Imler and Bulet, 2005].  However, 
Drosophila have a glial blood-brain barrier that may prevent direct activity of AMPs in neurons 
or it may be that protein aggregates, such as AB42, do not stimulate production of AMPs in 
Drosophila [Schirmeier and Klämbt, 2015].  It is possible that this particular Drosophila based 
model of AD cannot properly simulate an inflammatory response, which may be a limiting factor 
in this project, but could be valuable information for future studies of AD using Drosophila 
models.  Instead, such pathology in neurons may primarily activate glial cells to cleanup protein 
aggregates and damaged neurons.  In fact, glial activation has also been linked to inflammation 
and AD symptoms and could be measured as an alternative to inflammation in Drosophila [von 
Bernhardi, 2015].  It is also worth noting that Prx6 was found to be upregulated primarily in glial 
cells of AD patient brains, so it may be worth over-expressing dPrx2540 with a glial-specific 




dPrx2540, and mammalian Prx6, may have a complex role in AD.  PLA activity could be 
driving an inflammatory response as predicted, while the PRX activity could be compensating by 
reducing OS.  In the Drosophila AD models used for this study, no significant inflammation was 
detected in fly heads.  Therefore, it is possible that dPrx2540 may not drive inflammation in this 
model.  However, this does not account for the relatively large increase in lifespan seen 
repeatedly in males in which dPrx2540 expression was reduced by RNAi.   
 The second major objective of this ongoing project should help with refining 
interpretations of current data.  Currently, most of the major tools required for the second 
objective have been gathered.  Fly lines have been created with all endogenous copies of 
dPrx2540 removed via CRISPR.  Lines have also been generated carrying constructs for the 
expression of three varieties of mutant dPrx2540: (1) PRX activity ablated, (2) PLA2 activity 
ablated, and (3) both PRX and PLA2 activities ablated.  These are currently being crossed with 
the CRISPR dPrx2540 knockout line to generate recombinant lines which only expresses the 
desired dPrx2540 mutant genes.  These tools will allow very specific testing of the separate 
effects of each individual function of dPrx2540.  If expression of dPrx2540 with PRX activity 
removed accelerates mortality in the AD background, it might be concluded that PLA2 activity 
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